This observation, an assessment of how biological, genomic, and social factors contribute to race-based differences in OSA and AF, and a clearer understanding of the role of medications, such as GLP1-RA therapies, in the management of OSA, overall, and for racial and ethnic minoritized populations, represent ample opportunities for future research. This evidence concerns the gene GLP1R and obstructive sleep apnea syndrome.